NASDAQ · QNRX
Quoin Pharmaceuticals, Ltd.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for QNRX: Nov 05, 2026
Quoin Pharmaceuticals, Ltd. American Depositary Shares is expected to report earnings on 11/05/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.88. The reported EPS for the same quarter last year was $-6.71.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.88 | $-1.88 | $-1.88 | 1 |
| Dec 2026 | $-1.90 | $-1.90 | $-1.90 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · NASDAQ.com- RTTNews · Oct 14, 7:15 AM EDTQuoin Secures EMA Orphan Drug Designation For QRX003 In Rare Skin Disorder(RTTNews) – Quoin Pharmaceuticals Ltd. (QNRX) has received Orphan Drug Designation from the European Medicines Agency for QRX003 as a potential treatment for Peeling Skin Syndrome, a rare inherited skin disorder with significant unmet medical need. The designation marks another r
- RTTNews · Sep 23, 2:05 AM EDTQuoin Gets FDA Fast Track Designation For QRX003 In Peeling Skin Syndrome(RTTNews) – Quoin Pharmaceuticals, Ltd. (QNRX) announced that U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome.
- RTTNews · Sep 8, 9:47 AM EDTFDA Grants Rare Pediatric Disease Designation To Quoin's QRX003 For PSS(RTTNews) – Quoin Pharmaceuticals Ltd. (QNRX) announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS).
- RTTNews · Aug 28, 8:08 AM EDTQuoin Pharma Surges 45% In Pre-Market On Positive QRX003 Data And $50M Private Placement(RTTNews) – Quoin Pharmaceuticals, Inc. (QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced positive interim results from its ongoing Phase 2/3 study of QRX003 in Netherton Syndrome and a private placement financing of up
- RTTNews · Aug 14, 10:06 AM EDTQuoin Q2 Loss Widens; Gets FDA's Conditional Nod For QYLEKI Brand Name For QRX003(RTTNews) – Quoin Pharmaceuticals Ltd. (QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, reported second-quarter 2026 results and provided a corporate update highlighting progress across its QRX003 and QRX009 platforms.
- NASDAQ.com · Aug 13, 4:00 PM EDTPre-Market Earnings Report for August 14, 2026 : USAS, SGML, OTLK, STRR, PAVM, LFWD, CMCT, QNRX, ACXPThe following companies are expected to report earnings prior to market open on 08/14/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Americas Gold and Silver Corporation (USAS)is reporting for the quarter ending June 30, 2026. The consensus earni
- RTTNews · Jul 9, 9:28 AM EDTQuoin Receives FDA IND Clearance To Initiate Phase 2 Study Of QRX003 In Peeling Skin Syndrome(RTTNews) – Quoin Pharmaceuticals Ltd. (QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for QRX003 in Peeling Skin Syndrome. This clearance en
- RTTNews · Jul 9, 9:05 AM EDTQuoin Pharma To Launch Phase 2 Study Of QRX003 In Peeling Skin Syndrome After FDA Clearance(RTTNews) – Quoin Pharmaceuticals Ltd. (QNRX) on Thursday said the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), allowing the company to begin a Phase 2 study.
- RTTNews · Jun 24, 11:47 PM EDTTop Biotech Gainers: PLSM Inks Virtual Maternity Care Deal, ICCM Turns Heads, SLN Hits New High(RTTNews) – Today's top gainers include Pulsenmore, which has entered into a collaboration with Ouma Health, a provider of virtual maternity care solutions in the United States; IceCure Medical, whose ProSense technology was validated in an article published in the International
- RTTNews · Jun 23, 9:03 AM EDTQuoin Pharma: FDA Conditionally Accepts QYLEKI As Proposed Brand Name For QRX003(RTTNews) – Quoin Pharmaceuticals (QNRX) announced the FDA has conditionally approved QYLEKI as the proposed brand name for QRX003, the company's investigational product candidate for the treatment of Netherton Syndrome. The company said a request for proprietary name review and
- RTTNews · Jun 5, 1:57 AM EDTQuoin Receives Japan's MHLW Orphan Drug For QRX003 In Treating Netherton Syndrome(RTTNews) – Quoin Pharmaceuticals, Ltd. (QNRX), a late clinical-stage pharmaceutical company, announced that it has received the orphan drug designation for QRX003 from Japan's Ministry of Health, Labour and Welfare, or MHLW, for the treatment of a rare and severe genetic skin di
- RTTNews · Jun 3, 9:52 AM EDTQuoin Files IND For QRX003 To FDA In Treatment Of Peeling Skin Syndrome(RTTNews) – Quoin Pharmaceuticals, Ltd. (QNRX), a late clinical-stage pharmaceutical company, announced that it has submitted the Investigational New Drug application, or IND, for QRX003 to the U.S. Food and Drug Administration, or FDA, for the treatment of Peeling Skin Syndrome,
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Quoin Pharmaceuticals, Ltd. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.